Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

被引：0
|
作者：
Mai, Hai-Qiang [1 ]
Chen, Qiu-Yan [1 ]
Chen, Dongping [2 ]
Hu, Chaosu [3 ]
Yang, Kunyu [4 ]
Wen, Jiyu [5 ]
Li, Jingao [6 ]
Shi, Yingrui [7 ,8 ]
Jin, Feng [9 ]
Xu, Ruilian [10 ]
Pan, Jianji [11 ]
Qu, Shenhong [12 ]
Li, Ping [13 ]
Hu, Chunhong [14 ]
Liu, Yi-Chun [15 ]
Jiang, Yi [16 ]
He, Xia [17 ]
Wang, Hung-Ming [18 ]
Lim, Wan-Teck [19 ]
Xu, Rui-Hua [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
[3] Fudan Univ, Ctr Canc, Shanghai, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Affiliated Hosp Guangdong Med Univ, Zhanjiang, Peoples R China
[6] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[7] Xiangya Sch Med, Hunan Canc Hosp, Changsha, Peoples R China
[8] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[9] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China
[10] Shenzhen Peoples Hosp, Shenzhen, Peoples R China
[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China
[12] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[13] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[14] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China
[15] Taichung Vet Gen Hosp, Taichung, Taiwan
[16] Canc Hosp Shantou Univ, Coll Med, Shantou, Peoples R China
[17] Jiangsu Canc Hosp, Nanjing, Peoples R China
[18] Chang Gung Mem Hosp, Taoyuan, Taiwan
[19] Natl Canc Ctr, Singapore, Singapore
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT226
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Carrato, A.
    Swieboda-Sadlej, A.
    Staszewska-Skurczynska, M.
    Lim, R.
    Roman, L.
    Shparyk, Y.
    Bondarenko, I.
    Lin, X.
    Lechuga, M. J.
    Tursi, J. M.
    Sun, Y.
    De la Cruz, J. A.
    Jonker, D.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 19 - 19
  • [32] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [33] Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
    Zhou, Caicun
    Wu, Lin
    Fan, Yun
    Wang, Zhehai
    Liu, Lianke
    Chen, Gongyan
    Zhang, Li
    Huang, Dingzhi
    Cang, Shundong
    Yang, Zhixiong
    Zhou, Jianying
    Zhou, Chengzhi
    Li, Baolan
    Li, Juan
    Fan, Min
    Cui, Jiuwei
    Li, Yuping
    Zhao, Hui
    Fang, Jian
    Xue, Jianxin
    Hu, Chengping
    Sun, Ping
    Du, Yingying
    Zhou, Hui
    Wang, Shuyan
    Zhang, Wen
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1501 - 1511
  • [34] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [35] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y.
    Ohtsu, A.
    Van Cutsem, E.
    Rha, S. Y.
    Sawaki, A.
    Park, S.
    Lim, H.
    Wu, J.
    Langer, B.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [36] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)
    Leo, Di
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1923 - 1923
  • [37] Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
    Robert, Caroline
    Dummer, Reinhard
    Gutzmer, Ralf
    Lorigan, Paul
    Kim, Kevin B.
    Nyakas, Marta
    Arance, Ana
    Liszkay, Gabriella
    Schadendorf, Dirk
    Cantarini, Mireille
    Spencer, Stuart
    Middleton, Mark R.
    LANCET ONCOLOGY, 2013, 14 (08): : 733 - 740
  • [38] ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma
    Shen, Lin
    Lu, Zhihao
    Xu, Linxinyu
    Wang, Yan
    Zhou, Hui
    Liu, Ying
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Gemcitabine (G) plus cisplatin (C) plus radiotherapy in first-line treatment of locally advanced and metastatic undifferentiated carcinoma of the nasopharyngeal type (UCNT): Preliminary results of a phase II study.
    Adane, S
    Sadouki, M
    Mekki, F
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 517S - 517S
  • [40] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
12345